Phase I Dose Escalating Study of TKI258

Inclusion Criteria: * Written informed consent must be obtained prior to any screening procedures * Advanced solid tumors * Agreement to remaining hospitalized * ECOG performance status of 0 or 1 * Life expectancy of at least 3 months * Pregnant women. Male and female patients of reproductive potential must agree to employ an effective method of birth control * Demonstrate the specific hematological /blood chemistry laboratory values Exclusion Criteria: * Receipt of any investigational compound within 28 days prior to the first dose of study drug or failure to have recovered from the side effects of such prior therapy * Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and radiation therapy, within 28 days (with some exceptions) * Patients with CNS and/or leptomeningeal disease metastases * Presence or history of thromboembolic or cerebrovascular events * Impaired cardiac function or clinically significant cardiac disease * Malabsorption syndrome or uncontrolled gastrointestinal toxicities * Patients known to be HIV- or HBV- or HCV- positive * Patients with acute or chronic uncontrolled infection * Patients who have undergone surgery with general anesthesia for any cause within 28 days prior to the first dose of study drug * Patients who have been receiving anticoagulant therapy * Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14 days prior to the first dose of study drug * Patients who have been administering concomitant medication which may prolong the QTc interval * Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan * Patients with a large volume of ascitic and/or pleural fluid which requires drainage * Patients with any bone fractures * Deemed otherwise unsuitable by the investigator Other protocol-defined inclusion/exclusion criteria may apply